136 related articles for article (PubMed ID: 10638973)
21. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anaemia Survey (ECAS)?
Kosmidis P; Krzakowski M;
Lung Cancer; 2005 Dec; 50(3):401-12. PubMed ID: 16191450
[TBL] [Abstract][Full Text] [Related]
22. [Questionnaire-based survey on chemotherapy-induced anemia].
Tanaka A
Gan To Kagaku Ryoho; 2014 Apr; 41(4):421-5. PubMed ID: 24743357
[TBL] [Abstract][Full Text] [Related]
23. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.
Savonije JH; van Groeningen CJ; van Bochove A; Honkoop AH; van Felius CL; Wormhoudt LW; Giaccone G
Eur J Cancer; 2005 Jul; 41(11):1560-9. PubMed ID: 15953714
[TBL] [Abstract][Full Text] [Related]
24. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
[TBL] [Abstract][Full Text] [Related]
25. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.
Dunphy FR; Dunleavy TL; Harrison BR; Boyd JH; Varvares MA; Dunphy CH; Rodriguez JJ; McDonough EM; Minster JR; McGrady MD
Cancer; 1997 Apr; 79(8):1623-8. PubMed ID: 9118049
[TBL] [Abstract][Full Text] [Related]
26. Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.
Christodoulou C; Dafni U; Aravantinos G; Koutras A; Samantas E; Karina M; Janinis J; Papakostas P; Skarlos D; Kalofonos HP; Fountzilas G
Anticancer Res; 2009 Feb; 29(2):693-702. PubMed ID: 19331224
[TBL] [Abstract][Full Text] [Related]
27. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
Chang J; Couture F; Young S; McWatters KL; Lau CY
J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
[TBL] [Abstract][Full Text] [Related]
28. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
[TBL] [Abstract][Full Text] [Related]
29. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
Hollingsworth K; Romney MC; Crawford A; McAna J
J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
Bustos A; Álvarez R; Aramburo PM; Carabantes F; Díaz N; Florián J; Lázaro M; de Segovia JM; Gasquet JA; Alegre A;
Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
[TBL] [Abstract][Full Text] [Related]
31. Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
Voelter V; Schuhmacher C; Busch R; Peschel C; Siewert JR; Lordick F
Ann Thorac Surg; 2004 Sep; 78(3):1037-41. PubMed ID: 15337044
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-associated anaemia in patients with solid tumours. A retrospective evaluation and considerations relative to erythropoietin administration.
Locatelli MC; Tedeschi L; Clerici M; Romanelli A; D'Antona A; Labianca R; Luporini G
Support Care Cancer; 1996 May; 4(3):218-9. PubMed ID: 8739656
[TBL] [Abstract][Full Text] [Related]
33. Overnight transfusions in New Zealand hospitals: potential risk to patients.
Donegan R; Wright A; Bobbitt L; Charlewood R; Blacklock H
N Z Med J; 2016 Mar; 129(1431):30-7. PubMed ID: 27005871
[TBL] [Abstract][Full Text] [Related]
34. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy.
Waltzman R; Croot C; Justice GR; Fesen MR; Charu V; Williams D
Oncologist; 2005 Sep; 10(8):642-50. PubMed ID: 16177289
[TBL] [Abstract][Full Text] [Related]
35. The effects of anemia and blood transfusion on patients with stage III-IV ovarian cancer.
Altman AD; Liu XQ; Nelson G; Chu P; Nation J; Ghatage P
Int J Gynecol Cancer; 2013 Nov; 23(9):1569-76. PubMed ID: 24100588
[TBL] [Abstract][Full Text] [Related]
36. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group.
Ray-Coquard I; Le Cesne A; Rubio MT; Mermet J; Maugard C; Ravaud A; Chevreau C; Sebban C; Bachelot T; Biron P; Blay JY
J Clin Oncol; 1999 Sep; 17(9):2840-6. PubMed ID: 10561360
[TBL] [Abstract][Full Text] [Related]
37. Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
Chan A; Lim LL; Tao M
Singapore Med J; 2009 Apr; 50(4):365-70. PubMed ID: 19421679
[TBL] [Abstract][Full Text] [Related]
38. The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy.
Payne JK
Oncol Nurs Forum; 2002 Oct; 29(9):1334-40. PubMed ID: 12370703
[TBL] [Abstract][Full Text] [Related]
39. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA
Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486
[TBL] [Abstract][Full Text] [Related]
40. Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy.
Schouwink JH; Codrington H; Sleeboom HP; Kerkhofs LG; Wormhoudt LW
Eur J Cancer; 2008 Apr; 44(6):819-29. PubMed ID: 18343652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
